The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
KEYNOTE-204: Pembrolizumab versus brentuximab vedotin R/R classic Hodgkin lymphoma
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Lymphoma Hub was pleased to speak to John Kuruvilla, University of Toronto, CA, US. In this video, Dr Kuruvilla discusses the KEYNOTE-204 clinical trial results, investigating the use of pembrolizumab versus brentuximab vedotin in relapsed/refractory classic Hodgkin lymphoma.
This was a large, randomized phase III study, with progression-free survival as the primary endpoint. Toxicity results were also different among the two treatment groups and pneumonitis results were discussed for pembrolizumab.
KEYNOTE-204: Pembrolizumab versus brentuximab vedotin R/R classic Hodgkin lymphoma